What’s New in Psoriasis?

Target Audience

This multimedia program addresses identified knowledge and practice gaps among dermatology specialist physicians (MDs), nurse practitioners (NPs), and physician associates (PAs), while also encouraging changes in their clinical practice behaviors

Program Overview

Psoriasis affects approximately 3% of US adults, yet more than half of patients with moderate to severe disease remain undertreated, often managed with topical therapy alone despite qualifying for systemic treatment. This CME Circuit Training™ program addresses critical gaps in identifying candidates for oral therapy, understanding the clinical profiles and trial data for newly approved oral targeted agents, and tailoring treatment regimens through shared decision-making. Through 4 focused workout stations featuring case-based learning, expert faculty discussion, and practical decision support tools, clinicians will build the knowledge and skills needed to clear the bar for treating their patients with moderate to severe plaque psoriasis with oral targeted therapies.

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Identify adult and adolescent patients with psoriasis who are candidates for systemic therapy
2. Discuss the clinical rationale, trial results, and prescribing considerations for new oral targeted therapies for moderate to severe plaque psoriasis
3. Tailor treatment regimens for adult and adolescent patients with moderate to severe psoriasis based on disease presentation, therapeutic goals, treatment responses, and shared decision making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Andrew Blauvelt, MD:

• Consulting Fees: AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Bausch Health, Eli Lilly, Incyte, Janssen, Khanda Therapeutics, Leo, Novartis, Oruka, Pfizer, Re-AIM, Recludix, Regeneron, Sanofi, Sun Pharma, Takeda, UCB, and Zai Lab
• Speakers’ Bureaus: Eli Lily, UCB
• Ownership Interest – Stocks: Lipidio, Oruka 

Linda Stein Gold, MD: 

• Consulting Fees: AbbVie, Alumis, Arcutis, BMS, Galderma, Incyte, Kymera, J&J, Leo, Organon, Oruka, Pfizer, Regeneron, Sanofi, Takeda
• Speakers’ Beureaus: AbbVie, Alumis, Arcutis, BMS, Galderma, Incyte, Kymera, J&J, Leo, Organon, Pfizer, Regeneron, Sanofi, Takeda

The Integritas Communications planners and managers have no relevant financial relationships with ineligible companies to report. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.